The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...
A recent study found that combined tocilizumab and glucocorticoid therapy for at least 6 months did not fully eliminate ...
Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...
The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.
Findings showed tocilizumab-anoh had comparable efficacy, pharmacokinetics, safety, and immunogenicity with Actemra. The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab ...
GlobalData on MSN5d
Celltrion’s Avtozma receives FDA approval for multiple conditionsThe FDA's approval is grounded in an evidence totality and comprehensive data package, which includes outcomes from a study.
The first recipient of a gene-edited pig kidney died from cardiac causes 52 days after xenotransplantation. The world's first ...
CAMBRIDGE, Mass., February 06, 2025--2seventy bio, Inc. (Nasdaq: TSVT) today provided full-year Abecma® (idecabtagene ...
NYU Langone Health in New York City reportedly cancelled the appointments of two transgender children scheduled to receive ...
The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.
Testosterone worsens the damage caused by a heart attack by increasing the number of white blood cells released from the bone marrow. This is shown in a study by the University of Gothenburg, Sweden.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback